The American Society of Clinical Oncology (ASCO) recently updated its guideline on biomarkers with regard to the MammaPrint genetic test, concluding that in certain groups of breast-cancer patients, MammaPrint can better identify those who don’t require chemotherapy. The update was published in the Journal of Clinical Oncology (JCO). ASCO based its conclusion on results of… Continue reading Experts Disagree on Value of A Genetic Test for Breast-Cancer Patients